PDSB
PDS Biotechnology Corporation NASDAQ Listed Sep 30, 2015$1.16
Mkt Cap $64.5M
52w Low $0.51
46.0% of range
52w High $1.92
50d MA $0.84
200d MA $0.94
P/E (TTM)
-1.3x
EV/EBITDA
-171.6x
P/B
4.9x
Debt/Equity
561.2x
ROE
-81.8%
P/FCF
-0.0x
RSI (14)
—
ATR (14)
—
Beta
1.19
50d MA
$0.84
200d MA
$0.94
Avg Volume
716.0K
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.
25B Vreeland Road · Princeton, NJ 07932 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 30, 2026 | AMC | -0.20 | -0.14 | +30.0% | 0.54 | +0.7% | +12.8% | +0.2% | +4.7% | +22.9% | +17.6% | — |
| Nov 13, 2025 | AMC | -0.21 | -0.19 | +9.5% | 0.84 | +2.0% | -0.5% | -7.5% | +1.5% | -4.9% | +0.8% | — |
| Aug 13, 2025 | AMC | -0.24 | -0.21 | +12.5% | 1.16 | +0.0% | +3.4% | -0.8% | +4.2% | -5.6% | +0.0% | — |
| May 14, 2025 | AMC | -0.25 | -0.21 | +16.0% | 1.31 | +0.8% | +3.1% | +5.2% | +2.8% | +11.6% | -3.1% | — |
| Mar 27, 2025 | AMC | -0.29 | -0.21 | +27.6% | 1.25 | -5.6% | +0.8% | -5.6% | -9.2% | +7.4% | -9.5% | — |
| Nov 14, 2024 | AMC | -0.29 | -0.29 | +0.0% | 2.25 | -2.7% | -10.7% | -0.5% | +5.0% | -3.3% | +8.4% | — |
| Aug 13, 2024 | AMC | -0.31 | -0.23 | +25.8% | 3.05 | -1.6% | -1.0% | +7.0% | +0.6% | +8.3% | -1.7% | — |
| May 15, 2024 | AMC | -0.37 | -0.30 | +18.9% | 3.50 | +0.6% | +0.9% | -1.1% | -3.2% | +5.3% | -5.1% | — |
| Mar 27, 2024 | AMC | -0.39 | -0.34 | +12.8% | 3.85 | +1.6% | +2.9% | +1.5% | -7.5% | -1.1% | -10.6% | — |
| Nov 14, 2023 | AMC | -0.42 | -0.35 | +16.7% | 6.23 | -1.0% | +1.4% | +4.1% | -4.4% | +0.3% | -0.6% | — |
| Aug 14, 2023 | AMC | -0.37 | -0.37 | +0.0% | 5.33 | +0.4% | +10.3% | +6.0% | -9.3% | +0.5% | -1.2% | — |
| May 15, 2023 | AMC | -0.31 | -0.32 | -3.2% | 6.93 | -1.0% | -2.3% | +4.3% | +4.8% | +0.1% | +6.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.06 | $1.07 | +0.9% | +28.3% | -5.9% | +2.3% | -1.5% | +3.9% |
| Nov 25 | B. Riley Securities | Maintains | Buy → Buy | — | $0.76 | $0.75 | -0.6% | -1.5% | +9.1% | -5.2% | -6.9% | +7.0% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.96 | $0.95 | -1.4% | -12.3% | -0.5% | -7.5% | +1.5% | -4.9% |
| Jul 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.33 | $1.31 | -1.5% | -8.3% | +4.1% | +4.7% | -8.3% | +4.1% |
| Jun 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.68 | $1.68 | +0.0% | +4.2% | +2.3% | -2.2% | +1.7% | -9.0% |
| Mar 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.24 | $1.27 | +2.4% | +0.8% | +0.8% | -5.6% | -9.2% | +7.4% |
| Mar 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.19 | $1.22 | +2.5% | +5.9% | -2.4% | +8.9% | +3.7% | -2.9% |
| Mar 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.34 | $1.43 | +6.7% | -8.2% | -2.4% | +0.8% | -1.7% | +5.9% |
| Feb 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.34 | $1.36 | +1.5% | -5.2% | -0.8% | +22.2% | -11.7% | -2.2% |
| Dec 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.96 | $1.96 | +0.0% | -7.7% | -3.3% | -5.7% | +1.2% | -1.8% |
| Nov 25 | B. Riley Securities | Maintains | Buy → Buy | — | $2.09 | $2.14 | +2.4% | +3.8% | -2.8% | +1.9% | +1.9% | -1.8% |
| Nov 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.25 | $2.19 | -2.7% | -10.7% | -0.5% | +5.0% | -3.3% | +8.4% |
| Oct 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.12 | $3.10 | -0.6% | -0.3% | +0.3% | +5.8% | -2.4% | +0.0% |
| Oct 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.65 | $3.69 | +1.1% | +12.6% | -3.6% | -6.3% | +0.5% | -4.6% |
| Sep 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.06 | $3.07 | +0.3% | +2.0% | -1.6% | +4.6% | -0.3% | -1.9% |
| Aug 20 | Alliance Global Partners | Maintains | Buy → Buy | — | $3.52 | $3.55 | +0.9% | -1.7% | +0.6% | -5.2% | +1.5% | -5.1% |
| Aug 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.56 | $3.56 | +0.0% | -9.3% | -0.3% | -2.2% | -1.6% | -3.2% |
| Jun 12 | B. Riley Securities | Maintains | Buy → Buy | — | $2.76 | $2.86 | +3.6% | +6.2% | +2.4% | -7.0% | -4.3% | +2.6% |
| Jun 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.76 | $2.86 | +3.6% | +6.2% | +2.4% | -7.0% | -4.3% | +2.6% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.54 | $3.72 | +5.1% | -1.1% | +0.9% | -1.1% | -3.2% | +5.3% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.02 | $4.05 | +0.7% | -4.7% | -8.4% | +2.3% | -1.4% | -1.1% |
| Mar 28 | B. Riley Securities | Maintains | Buy → Buy | — | $3.85 | $3.91 | +1.6% | +2.9% | +1.5% | -7.5% | -1.1% | -10.6% |
| Mar 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.48 | $4.00 | -10.7% | -14.1% | +2.9% | +1.5% | -7.5% | -1.1% |
| Nov 15 | Oppenheimer | Maintains | Outperform → Outperform | — | $6.23 | $6.17 | -1.0% | +1.4% | +4.1% | -4.4% | +0.3% | -0.6% |
| Oct 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.81 | $4.79 | -0.4% | -3.3% | -4.3% | +1.3% | +0.4% | +1.5% |
| Sep 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.22 | $5.25 | +0.6% | -2.3% | -1.4% | +0.4% | -6.9% | -14.5% |
| Sep 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.34 | $5.38 | +0.7% | -1.1% | +0.4% | -1.7% | -1.9% | +2.2% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.85 | $5.00 | +3.1% | +9.9% | +10.3% | +6.0% | -9.3% | +0.5% |
| Jun 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.53 | $7.27 | +11.3% | -4.4% | -5.3% | -1.5% | +1.4% | +4.1% |
| May 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.72 | $8.16 | +21.4% | +27.4% | -1.1% | +13.1% | +3.3% | -4.8% |
| May 26 | Oppenheimer | Maintains | Outperform → Outperform | — | $6.72 | $8.16 | +21.4% | +27.4% | -1.1% | +13.1% | +3.3% | -4.8% |
| May 16 | Oppenheimer | Maintains | Outperform → Outperform | — | $6.93 | $6.86 | -1.0% | -2.3% | +4.3% | +4.8% | +0.1% | +6.3% |
| Apr 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.59 | $6.60 | +0.2% | -3.9% | -3.0% | -3.6% | +2.7% | +0.0% |
| Mar 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.02 | $6.05 | +0.5% | -2.7% | +4.9% | -1.5% | -5.3% | -4.0% |
| Mar 29 | B. Riley Securities | Maintains | Buy → Buy | — | $5.85 | $5.96 | +1.9% | +2.9% | -2.7% | +4.9% | -1.5% | -5.3% |
| Mar 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.68 | $5.61 | -1.2% | +3.0% | +2.9% | -2.7% | +4.9% | -1.5% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.73 | $7.68 | -0.6% | -1.0% | +1.4% | -9.5% | +3.8% | -3.0% |
| Jan 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.20 | $12.50 | -5.3% | -19.5% | +12.9% | -3.2% | -2.0% | -3.2% |
| Dec 12 | B. Riley Securities | Maintains | Buy → Buy | — | $8.72 | $8.77 | +0.6% | +1.6% | +0.1% | +3.7% | +2.6% | -1.1% |
| Nov 15 | Chardan Capital | Maintains | Buy → Buy | — | $7.06 | $7.28 | +3.1% | +22.9% | -2.3% | +10.1% | -7.4% | -4.7% |
| Nov 1 | B. Riley Securities | Maintains | Buy → Buy | — | $5.24 | $5.42 | +3.4% | +5.0% | -7.8% | +1.4% | -3.1% | +6.6% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.59 | $10.58 | -0.1% | +2.8% | -2.2% | -5.3% | -1.9% | +2.4% |
| Jun 28 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $11.00 | $11.71 | +6.5% | +6.5% | +0.0% | +7.2% | -1.4% | -3.8% |
| Jun 9 | Chardan Capital | Maintains | Buy → Buy | — | $11.16 | $12.06 | +8.1% | +6.0% | +5.5% | -3.4% | +6.6% | -28.5% |
| Jun 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.86 | $11.39 | +4.9% | +4.1% | +0.0% | +13.1% | -26.4% | +18.7% |
| May 20 | Chardan Capital | Maintains | Buy → Buy | — | $5.74 | $6.20 | +8.0% | +26.7% | +14.6% | +5.0% | -0.8% | +19.2% |
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.92 | $5.16 | +4.9% | +9.1% | -0.4% | -6.7% | -11.8% | +1.1% |
| May 27 | Alliance Global Partners | Maintains | Buy → Buy | — | $1.17 | $1.26 | +7.7% | +4.3% | +2.5% | +4.8% | -6.9% | +5.7% |
| Mar 30 | H.C. Wainwright | Downgrade | Buy → Neutral | — | $0.74 | $0.77 | +3.5% | +1.4% | -2.8% | -7.4% | -3.9% | +3.5% |
| Mar 30 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $0.74 | $0.77 | +3.5% | +1.4% | -2.8% | -7.4% | -3.9% | +3.5% |
No insider trades available.
8-K · 8.01
!! High
PDS Biotechnology Corporation -- 8-K 8.01: Material Event / Announcement
PDS Biotechnology updated its corporate presentation deck, likely signaling new strategic messaging or operational developments that investors should review for updated company positioning and guidance.
Apr 24
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Positive interim data from PDS Biotech's colorectal cancer combination trial shows potential in a difficult-to-treat patient population, de-risking their lead candidate and supporting stock appreciation prospects.
Apr 15
8-K
Unknown — 8-K Filing
PDS Biotech achieved clinical progress and IP gains in 2024, suggesting pipeline advancement that could validate its therapeutic approach and potentially drive stock appreciation if upcoming trial data proves positive.
Mar 30
8-K
PDS Biotechnology Corporation -- 8-K Filing
PDS Biotechnology (PDSB) received a Nasdaq notice of non-compliance with minimum bid price requirements but has until 180 days to regain compliance or face potential delisting.
Mar 3
8-K · 8.01
!! High
PDS Biotechnology Corporation -- 8-K 8.01: Material Event / Announcement
PDS Biotechnology updated its corporate presentation deck, likely signaling potential strategic announcements or operational progress that investors should review for material developments.
Feb 23
8-K · 8.01
!! High
PDS Biotechnology Corporation -- 8-K 8.01: Material Event / Announcement
PDS Biotechnology added progression-free survival as an interim primary endpoint in its Phase 3 VERSATILE-003 trial, potentially enabling accelerated FDA approval for PDS0101 in HPV16-positive head and neck cancer.
Feb 20
Data updated apr 26, 2026 7:08pm
· Source: massive.com